Mizuho Cuts MiMedx Group (NASDAQ:MDXG) Price Target to $10.00

MiMedx Group (NASDAQ:MDXG) had its price target cut by Mizuho from $12.00 to $10.00 in a research report report published on Wednesday,Benzinga reports. They currently have an outperform rating on the stock.

Several other research analysts also recently issued reports on the company. Wall Street Zen upgraded MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 2nd. Weiss Ratings reissued a “hold (c)” rating on shares of MiMedx Group in a research report on Monday. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $11.00.

MiMedx Group Trading Down 2.8%

Shares of MDXG stock opened at $7.05 on Wednesday. The stock has a market cap of $1.04 billion, a P/E ratio of 26.11 and a beta of 1.64. The company has a quick ratio of 3.95, a current ratio of 4.41 and a debt-to-equity ratio of 0.07. MiMedx Group has a fifty-two week low of $5.79 and a fifty-two week high of $9.71. The business has a fifty day simple moving average of $7.02 and a 200-day simple moving average of $6.86.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings data on Monday, November 13th. The company reported ($0.03) EPS for the quarter. MiMedx Group had a net margin of 10.38% and a return on equity of 27.19%. The business had revenue of $67.69 million during the quarter. On average, analysts forecast that MiMedx Group will post 0.3 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other MiMedx Group news, insider Kimberly Maersk-Moller sold 58,300 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $7.42, for a total transaction of $432,586.00. Following the transaction, the insider owned 236,982 shares of the company’s stock, valued at $1,758,406.44. This represents a 19.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 1.70% of the company’s stock.

Institutional Investors Weigh In On MiMedx Group

A number of hedge funds and other institutional investors have recently made changes to their positions in MDXG. Deutsche Bank AG lifted its position in MiMedx Group by 144.2% during the first quarter. Deutsche Bank AG now owns 321,296 shares of the company’s stock worth $2,442,000 after buying an additional 189,750 shares during the period. Invesco Ltd. increased its stake in shares of MiMedx Group by 34.6% during the 1st quarter. Invesco Ltd. now owns 76,123 shares of the company’s stock valued at $579,000 after acquiring an additional 19,558 shares during the last quarter. Nuveen LLC purchased a new position in shares of MiMedx Group during the 1st quarter worth about $2,355,000. Russell Investments Group Ltd. lifted its holdings in shares of MiMedx Group by 262.5% during the 1st quarter. Russell Investments Group Ltd. now owns 26,114 shares of the company’s stock worth $198,000 after acquiring an additional 18,911 shares during the period. Finally, American Century Companies Inc. boosted its position in shares of MiMedx Group by 36.0% in the first quarter. American Century Companies Inc. now owns 270,808 shares of the company’s stock worth $2,058,000 after acquiring an additional 71,739 shares during the last quarter. Hedge funds and other institutional investors own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.